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Purpose: Fragility fractures are a clinical conse-
quence of osteoporosis (OP). Evidence suggests
however, current OP treatments may be inadequate
in reducing fracture risk. The purpose of this study
was to estimate the proportion and characteristics of
Swedish patients who remain at high risk of fracture
after 2 years of treatment, as evidenced by osteopor-
otic bone mineral density (BMD), a decrease in BMD,
or the occurrence of new fractures.
Methods: This was a retrospective, descriptive
analysis of a subset of participants obtained from a
Swedish osteoporosis patient registry from 1991 to
2009. Patients were required to be osteoporotic, to be
treatment naive at baseline, to have returned for at
least 1 follow-up visit, and to have reported osteo-
porosis treatment use for Z2 years after the baseline
visit with a BMD T score. Two overlapping cohorts
remaining at high risk of fracture were deﬁned using
the BMD T score measured after 2 years of treatment
from baseline. The osteoporosis cohort comprised
patients who remained osteoporotic, whereas the
BMD decrease cohort included patients whose total
hip or lumbar spine T score decreased by Z3%.
Findings: A total of 3292 osteoporotic patients
were identiﬁed in the registry, of whom 392 met the
study inclusion criteria. The mean (SD) patient age
was 68.3 (8.5) years, with most patients being female
(92.3%). Among all patients, 297 (75.8%) remained
osteoporotic after at least 2 years of treatment, 90
(23.0%) experienced a BMD decrease of Z3%, and
23 (5.9%) reported an incident fracture between the
baseline and ﬁrst follow-up visit. More than three-
quarters (76.8%) of all patients reported taking1686bisphosphonates, whereas only 72.4% and 47.8%
reported this in the osteoporosis and BMD decrease
cohorts, respectively. Raloxifene was the only nonbi-
sphosphonate used, with 24.2% of all patients re-
portedly taking it.
Implications: This study highlighted that despite 2
years of osteoporosis treatment, a high percentage of
patients remain at high risk of fracture. There is a need
for improved treatment strategies that reduce fracture
risk and improve patient outcomes in the real-world
setting. (Clin Ther. 2016;38:1686–1695) & 2016 The
Authors. Published by Elsevier HS Journals, Inc.
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INTRODUCTION
Osteoporosis is a skeletal disorder characterized by
compromised bone strength and disruption of bone
architecture that results in increased risks of fragility
fractures, representing the predominant clinical
consequence of osteoporosis. Fragility fractures
contribute to the signiﬁcant societal burden through
the loss in quality of life attributable to associated
pain, disability, substantial incremental health care
costs, and higher mortality.1
The prevalence of osteoporosis is common in
Sweden, with approximately 1 in 3 women aged 70Volume 38 Number 7
D. Mellstro¨m et al.to 79 years diagnosed as having osteoporsis.2 In 2010,
there were an estimated 107,000 incident fractures
among Swedish adults 50 years and older, with most
occurring among women (66%). By 2025, the annual
fracture incidence is expected to increase by 26%
to 135,000, primarily as a function of an aging
population.3 The health care costs associated with
osteoporosis in Sweden are substantial. In 2005, the
total annual fracture-related costs were estimated at
3.2% of total Swedish health care costs.4 The
economic burden is expected to continue to increase
in Sweden from an estimated €1.5 billion in 2010 to
€1.8 billion by 2025, an increase of 23%.3
The World Health Organization operationally
deﬁnes osteoporosis as a bone mineral density
(BMD) that is Z2.5 SDs below the mean value for a
healthy young adult (T score o2.5 SDs).1 Several
pharmacologic therapies are available for patients
with osteoporosis or at high risk of fracture.5 For
patients with osteoporosis, the aim of treatment is to
slow the decrease in BMD and decrease fracture
risk. In Sweden, osteoporosis treatments include
bisphosphonates, estrogen agents, selective estrogen
receptor modulators, parathyroid hormone, and
denosumab.2,6 Current Swedish guidelines for
osteoporosis treatment are based on an algorithm
that incorporates BMD T score, fracture risk,7 and
prior fracture.6 Recommended treatments include
alendronate as ﬁrst-line therapy, zoledronic acid as
second-line therapy, and risedronate and denosumab
as alternative therapies. Raloxifene, strontium rane-
late, teriparatide, and ibandronate are lower-priority
treatment options.6
There is evidence to suggest that current osteopo-
rosis treatment may be inadequate in reducing
fracture risk, even under the well-controlled con-
ditions of clinical trials.8,9 There is no universally
accepted deﬁnition of treatment failure; however,
BMD decrease, incident fractures, and changes in
markers of bone turnover are commonly used in
clinical practice to measure fracture risk.10 Diez-
Perez and Gonzalez-Macias8 reported that in 5
clinical trials11–15 8.0% to 12.4% of patients expe-
rienced fractures despite being treatment adherent
(correctly taking at least 80% of doses). Observa-
tional evidence from Europe, Canada, and the
United States found that 10% to 50% of patients
experienced loss in BMD, persistently low BMD T
scores, and/or fracture while undergoing activeJuly 2016osteoporosis therapy.9,16–21 For osteoporotic pa-
tients at high risk of fracture (ie, baseline BMD T
scoreo2.5), 25.8% experienced BMD decrease or
multiple fractures.9
Swedish men and women have the second highest
age-standardized risk of hip fracture in the world.22
However, despite this high fracture rate, studies
examining Swedish patients undergoing active
osteoporosis therapy who are at high risk of fracture
have not been published. Several studies conducted on
patients in European countries have examined patients
at high risk of fracture,9,19,20,23,24 with most studies
focusing exclusively on patients taking bisphospho-
nates,9,17–21 neglecting the alternative nonbisphos-
phonate therapies available in Sweden.6 To provide
insight into the high fracture rate in Sweden, a
retrospective study was conducted on a cohort of
osteoporotic patients identiﬁed from a Swedish
registry. The objective was to identify the proportion
and characteristics of Swedish patients who remain
at high risk of fracture after 2 years of active
osteoporosis treatment, as evidenced by osteoporotic
BMD, a decrease in BMD, or the occurrence of new
fractures.PATIENTS AND METHODS
Study Design
This study was a retrospective, descriptive analysis
of data from a Swedish osteoporosis patient registry
from 1991 to 2009. Studies that use data collected
from patient registries may provide substantial
information that contributes to the understanding of
the incidence, treatment patterns, outcomes, and
other descriptive characteristics of disease.25 The
registry was established at the osteoporosis clinic at
Sahlgrenska University hospital in Gothenburg, a
region in the west of Sweden that encompasses
approximately 2 million people. Patients were
referred to the osteoporosis clinic by general
practitioners, gynecologists, and other providers of
dual energy X-ray absorptiometry scans to assess
BMD. This ﬁrst clinic visit was classiﬁed as the
baseline visit. On the basis of clinical recommenda-
tion, patients were referred back to the clinic for
follow-up every 2 years. The ﬁrst follow-up visit was
the visit at least 2 years after the baseline clinic.
Recommendations for follow-up visits were advised
for patients diagnosed as having osteopenia (T score1687
Clinical Therapeuticsof 42.5 to o1) or osteoporosis (T-score r2.5).
Few patients had 41 follow-up visit. The data
collected were captured in the registry. Because the
study was a retrospective patient registry analysis that
used deidentiﬁed data, no ethics approval was
required.
Patient Selection and Study Cohort Definition
The study included all patients identiﬁed in the
registry who (1) were osteoporotic at the baseline
clinic visit as evidenced by a total hip or lumbar spine
T score of r2.5; (2) had at least 1 follow-up visit
after baseline; (3) were osteoporosis treatment naive
before baseline as reported in the patient question-
naire (see Appendix); and (4) received pharmacologic
therapy for at least 2 years after baseline. osteop-
orosis treatment was deﬁned as active pharmacologic
therapy with bisphosphonates (alendronate, risedron-
ate, and etidronate) and nonbisphosphonates (ralox-
ifene and teriparatide). Calcium and vitamin D were
considered nonosteoporosis treatment.
The study cohorts were deﬁned based on T scores
of the hip and lumbar spine because these are
commonly used to inform high fracture risk.26–28
Eligible patients were assigned to 2 overlapping
cohorts: (1) osteoporosis and (2) BMD decrease.
The cohorts were deﬁned according to the BMD
T score measured at the ﬁrst follow-up visit. The
osteoporosis cohort comprised osteoporotic patients
with T scoresr2.5 at the hip or lumbar spine at the
ﬁrst follow-up visit. The BMD decrease cohort
consisted of patients whose total hip or lumbar
spine T score decreased by Z3% between baseline
and the ﬁrst follow-up visit. Patients who were
deemed not osteoporotic were not required to return.
Measures
Data from the baseline and follow-up visit sched-
uled every other year were captured in the registry.
At baseline, demographic (age, sex) and clinical
(height, weight, total hip, and lumbar spine T score)
characteristics and physician diagnosis (evidenced by a
total hip or lumbar spine T score r2.5) were
extracted from the registry. Other characteristics
captured at baseline were obtained from a patient
questionnaire (see Appendix) and included the follow-
ing: smoking status, back pain, family history of
fractures, history of falls, fractures after the age of
40 years, and current and previous use of osteoporosis1688pharmacotherapy and other nonosteoporosis medi-
cations, such as calcium and vitamin D.
At each follow-up visit, T scores were extracted
from the registry, and the patient questionnaire was
repeated. The T score at ﬁrst follow-up visit was the
regarded as the ﬁnal T score used to assign patients to
the osteoporosis or BMD decrease cohort. To deter-
mine the use of osteoporosis pharmacotherapy during
the interval from baseline to the ﬁrst follow-up visit,
patients were asked which osteoporosis medications
they were taking at the ﬁrst follow-up visit. No
attempt was made to verify or conﬁrm these patients
self-reported use of osteoporosis medications or the
patients’ adherence level, medications switches, or
therapy discontinuations from medical records.
Patients could report taking 41 osteoporosis medi-
cation. Osteoporosis fractures that occurred between
the baseline and ﬁrst follow-up visits were patient-
reported at each follow-up visit.
Statistical Analysis
Descriptive statistics were used to report study
results. Fracture and T score data, as well as demo-
graphic characteristics, baseline medications and sup-
plement use, and other risk factors, were summarized
for all participants and by study cohort. The number
and proportion of patients who remained osteopor-
otic, who experienced a BMD T score decrease from
baseline, or a fracture during follow-up were reported.
Other clinical characteristics were described using
summary statistics. Because the study was descriptive,
no comparisons were planned or conducted.
Statistical analysis was conducted using SAS stat-
istical software (SAS Institute, Cary, North Carolina).
Before analysis, the data were audited and cleaned at
an observation level. Any inconsistencies and/or
missing data issues were discussed and resolved. Data
with missing values were treated as such, and no
imputations were conducted. Continuous variables
were described using means and SDs. Binary and
polychotomous variables were summarized in terms
of the number and proportion of patients.RESULTS
Patient Selection and Characteristics
A total of 9312 patients enrolled in the registry
from 1991 to 2009. Of these, 3292 patients (35.4%)
were osteoporotic at baseline as indicated by a BMD
of r2.5 at either the total hip or lumbar spine. AVolume 38 Number 7
Patients enrolled in registry
N = 9312 (100%)
n = 3292 (35.4%)
n = 1858 (20.0%)
n = 1798 (19.3%)
n = 392 (4.2%)
Baseline BMD  <–2.5 (hip or spine)
Returned for a second BMD measurement
Treatment naïve at baseline
Treatment duration >2 years
–
–
Figure 1. Patient selection. BMD ¼ bone mineral
density.
D. Mellstro¨m et al.total of 392 patients (4.2%) met the inclusion criteria
and were included in 2 overlapping cohorts. Figure 1
provides a summary of the patient selection process.
Table I summarizes the baseline characteristics of
all included patients and by the predeﬁned follow-up
cohorts. Mean (SD) age for the osteoporosis cohort
was 67.5 (8.6) years, and for the BMD decrease
cohort was 68.5 (8.4) years. Mean (SD) age of all
eligible patients was 68.3 (8.5) years. The mean (SD)
body mass index was 24.0 (4.4) kg/m2 in the BMD
decrease group, 31.6 (92.3) kg/m2 in the osteoporosis
cohort, and 29.9 (80.1) kg/m2 in all eligible patients.
Less than one-tenth (8.7%) of eligible patients
reported using nonosteoporosis medications, such
as calcium and vitamin D. Most patients (88.0%)
reported never smoking.
The overall proportions of patients with osteopo-
rosis of the hip and lumbar spine at baseline were
46.8% and 85.7%, respectively. The proportion of
patients with T scoresr2.5 in the lumbar spine was
almost double that in the total hip; the percentages of
patients in the osteoporosis cohort with osteoporosis
of the hip and lumbar spine were 51.4% and 88.9%,
respectively. The percentages of patients with fracturesJuly 2016after 40 years of age in the BMD decrease cohort,
the osteoporosis cohort, and all eligible patients were
12.9%, 8.9%, and 13.5%, respectively. Overall,
14.8% of patients had a parental history of fracture.
Falls reported during the past year at baseline were
19.9% among the osteoporosis cohort, 14.4% in the
BMD decrease cohort, and 22.4% in all eligible
patients. Overall, daily back pain was reported by
11.0% of all patients; this was 9.4% in the osteopo-
rosis cohort and 6.7% in the BMD cohort. Most
patients reported never smoking.
Osteoporosis Treatment Patterns
All eligible patients were treatment naive at base-
line. Table II provides a summary of the osteoporosis
pharmacotherapy taken during the previous 2 years as
reported by patients at the ﬁrst follow-up visit. Most
of all eligible patients reported using bisphosphonates
(76.8%); use among the BMD decrease cohort was
notably lower (47.8%) than in the osteoporosis
cohort (72.4%). Overall, 70 mg once weekly of
alendronate was the most common bisphosphonate
prescribed to patients. In contrast, the use of ralox-
ifene, the only nonbisphosphonate prescribed, was
53.3% in the BMD decrease cohort and 24.2% in
all eligible patients. The use of both bisphosphonate
and nonbisphosphonate medications was reported in
4 patients.
Fracture and BMD T Score Change From
Baseline
The frequency of fracture and change in BMD T
score from baseline to the ﬁrst follow-up visit are
given in Table III. The mean (SD) time to ﬁrst follow-
up visit was 2.71 (0.98) years. Results indicate that
297 patients (75.8%) remained osteoporotic at either
the total hip or lumbar spine after at least 2 years of
treatment. Ninety patients (23.0%) experienced a
BMD decrease Z3%. All patients in the BMD decline
cohort had a decrease in T score Z3%, yet only 90%
remained osteoporotic. This ﬁnding is because osteo-
porosis is deﬁned as BMD in lumbar spine or hip.
Some patients may have a BMD decrease in the hip,
for example, but not in the lumbar spine, yet not be
considered osteoporotic. Extensive overlap occurred
among the osteoporosis and BMD decrease cohorts:
90% of patients in the BMD decrease cohort remained
osteoporotic, and 27.3% of osteoporosis cohort
patients experienced aZ3% T score decrease at either1689
Table I. Baseline characteristics of all patients and by follow-up cohort.
Characteristic All Patients Osteoporosis Cohort* BMD Decrease Cohort†
No. (%) 392 (100.0) 297 (75.8) 90 (23.0)
Age, mean (SD), y 68.3 (8.5) 67.5 (8.6) 68.5 (8.4)
Female, No. (%) 362 (92.3) 294 (96.7) 72 (93.9)
Height, mean (SD), cm 158.5 (28.3) 157.1 (30.6) 158.3 (31.3)
Weight, mean (SD), kg 62.1 (15.5) 60.8 (16.1) 62.4 (17.6)
BMI, mean (SD), kg/m2 29.9 (80.1) 31.6 (92.3) 24.0 (4.2)
Osteoporosis, No. (%)
Total hip
Normal‡ 31 (7.9) 20 (6.8) 9 (10.0)
Osteopenia§ 177 (45.3) 124 (41.9) 44 (48.9)
Osteoporosis|| 183 (46.8) 152 (51.4) 37 (41.1)
Lumbar spine
Normal‡ 16 (4.1) 9 (3.0) 6 (6.7)
Osteopenia§ 40 (10.2) 24 (8.1) 10 (11.1)
Osteoporosis|| 336 (85.7) 264 (88.9) 74 (82.2)
Fractures after 40 years of age, No. (%)¶ 53 (13.5) 38 (12.8) 8 (8.9)
Parental history of fracture, No. (%)¶ 58 (14.8) 42 (14.1) 9 (10.0)
Falls during past year, No. (%)¶
0 304 (77.6) 238 (80.1) 77 (85.6)
1 47 (12.0) 31 (10.4) 6 (6.7)
2 30 (7.7) 23 (7.7) 5 (5.6)
3 7 (1.8) 3 (1.0) 1 (1.1)
4 3 (0.8) 1 (0.3) 1 (1.1)
5 1 (0.3) 1 (0.3) 0
Medications taken, No. (%)¶
Calcium and vitamin D 34 (8.7) 24 (8.1) 6 (6.7)
Estrogen 18 (4.6) 11 (3.7) 3 (3.3)
Cortisone 10 (2.6) 7 (2.4) 1 (1.1)
Daily back pain, No. (%)¶ 43 (11.0) 28 (9.4) 6 (6.7)
Never smoked, No. (%)¶ 345 (88.0) 264 (88.9) 83 (92.2)
BMD ¼ bone mineral density.
*T score r–2.5 at either hip or lumbar spine after Z2 years of treatment.
†T score decrease Z3% at either hip or lumbar spine after Z2 years of treatment.
‡Deﬁned as T score Z1.
§Deﬁned as T score of o2.5 to o–1.
||Deﬁned as T score r–2.5.
¶Patient reported.
Clinical Therapeuticsthe hip or lumbar spine. Of note, 20.7% of patients
who remained osteoporotic also experienced a
decrease in BMD.
The mean (SD) BMD T score change from baseline
to ﬁrst follow-up visit for all eligible patients was an1690increase of 0.26 (0.53) at total hip and 0.43 (0.65) at
lumbar spine. Although there was a mean (SD)
improvement in total hip T score observed in the
osteoporosis cohort of 0.22 (0.55), this was not seen
in the BMD decrease cohort (0.09 [0.61]) despiteVolume 38 Number 7
Table II. Osteoporosis treatment patterns from baseline to first follow-up visit.
Osteoporosis Treatment
No. (%) of Patients
All Patients
(N ¼ 392)
Osteoporosis Cohort*
(n ¼ 297)
BMD Decrease Cohort†
(n ¼ 90)
Bisphosphonate 301 (76.8) 215 (72.4) 43 (47.8)
Alendronate, 10 mg once daily 75 (19.1) 54 (18.2) 9 (10.0)
Alendronate, 70 mg once weekly 107 (27.3) 69 (23.2) 7 (7.8)
Risedronic acid, 5 mg once daily 43 (11.0) 33 (11.1) 9 (10.0)
Risedronic acid, 35 mg once weekly 37 (9.4) 27 (9.1) 7 (7.8)
Etidronic acid‡ 52 (13.3) 43 (14.5) 14 (15.6)
Nonbisphosphonate§ 95 (24.2) 86 (29.0) 48 (53.3)
BMD ¼ bone mineral density.
*T score r–2.5 at either hip or lumbar spine after Z2 years of treatment.
†T score decrease Z3% at either hip or lumbar spine after Z2 years of treatment.
‡No dosing data in survey.
§Raloxifene only.
D. Mellstro¨m et al.active treatment. Increases in lumbar spine T scores
between baseline and ﬁrst follow-up visit were
recorded across all cohorts. The mean (SD) changes
in BMD T score were 0.43 (0.65) for lumbar spine
and 0.26 (0.53) for the total hip between the baseline
and ﬁrst follow-up visit.DISCUSSION
This study provides real-world evidence on the pro-
portion of Swedish patients who remain at high risk of
fracture after 2 years of active osteoporosis treatment.
Most patients in the study remained osteoporotic
(75.8%), despite reported improvements in T scores
in both total hip and lumbar from baseline to ﬁrst
follow-up. Almost a quarter (23.0%) experienced a
Z3% decrease in total hip or lumbar spine T score,
and more than one-ﬁfth (20.7%) were both osteopor-
otic and experienced a decrease in BMD during that
same period. Despite 2 years of active osteoporosis
treatment and improvements in T scores, incident
fractures occurred in 5.9% of all eligible patients
between the baseline and ﬁrst follow-up visit.
Patients were assessed as high risk of fracture after
treatment based on an osteoporotic BMD T score, a
decrease in BMD T score, or the presence of a
fracture. On average, BMD T scores increased afterJuly 2016the 2-year follow-up period (þ0.26 at total hip and
þ0.43 at lumbar spine). However, these increases
were small and may explain the fact that 75.8% of
all eligible patients remained osteoporotic and at high
risk of fracture after 2 years of treatment. Curiously,
despite all patients in the BMD decrease cohort having
a decline in T score Z3%, only 90% remained
osteoporotic. One explanation may be that some
individuals experienced uneven BMD gains, for
example, T score gains at the lumbar spine with a
corresponding decline at the hip.
As previously noted, in addition to patients remain-
ing osteoporotic, 23.0% of patients had a decrease in
BMD, which was higher when compared with pre-
vious studies. The Canadian Database for Osteopo-
rosis and Osteopenia Patients (CANDOO) study was
a prospective cohort of 1588 Canadian patients older
than 50 years taking bisphosphonates for 2 years.21
The authors found 16.2% of patients lost at least 3%
BMD at the hip or spine while undergoing active
therapy. Similarly, the 2014 prospective study by
Cairoli et al9 of 97 postmenopausal women found
that 16.5% of patients experienced a BMD decrease
higher than the least signiﬁcant change after 36
months of bisphosphonate therapy. A number of
clinical and lifestyle factors may contribute to BMD
decrease, which may partly explain the higher1691
Table III. Occurrence of fracture and BMD T score change from baseline to first follow-up visit.
Characteristic All Patients
(N ¼ 392)
Osteoporosis
Cohort* (n ¼ 297)
BMD Decrease
Cohort† (n ¼ 90)
Time from baseline to ﬁrst follow-up visit,
mean (SD), y
2.71 (0.98) 2.70 (1.00) 2.76 (1.04)
Remained osteoporotic,‡ No. (%) 297 (75.8) 297 (100.0) 81 (90.0)
T score decreaseZ3% at either hip or lumbar spine 90 (23.0) 81 (27.3) 90 (100.0)
Baseline T score, mean (SD)
Total hip –2.30 (0.93) –2.42 (0.92) –2.15 (0.92)
Lumbar spine –3.00 (0.98) –3.14 (1.01) –2.81 (1.26)
Final T score, mean (SD)
Total hip –2.04 (0.97) –2.20 (0.97) –2.24 (0.96)
Lumbar spine –2.57 (1.05) –2.82 (1.01) –2.80 (1.09)
T score change from baseline, mean (SD)
Total hip 0.26 (0.53) 0.22 (0.55) –0.09 (0.61)
Lumbar spine 0.43 (0.65) 0.32 (0.61) 0.02 (0.94)
Fracture (1þ)
From baseline to ﬁrst follow-up visit, n (%) 23 (5.9) 10 (3.4) 4 (4.4)
After ﬁrst follow-up visit among patients with
Z3 visits, No./total No. (%)
5/48 (10.4) 4/36 (11.1) 2/12 (16.7)
BMD - bone mineral density.
*T score r–2.5 at either hip or lumbar spine after Z2 years of treatment.
†T score decrease Z3% at either hip or lumbar spine after Z2 years of treatment.
‡Final T score r–2.5 at hip or lumbar spine.
Clinical Therapeuticspercentage of BMD decrease in the present study.
Notably, only 8.7% of patients in the present study
were taking calcium or vitamin D supplements at
baseline compared with all patients in the CANDOO
study and 92.8% of patients in the latter study.
Calcium supplementation, with or without vitamin
D, is known to reduce the rate of BMD decrease at the
hip and spine.29 The study by Cairoli et al9 only
included patients with adequate treatment adherence
in their analysis to assess treatment failure. The
possibility remains that patients with poorer
treatment adherence in the present study are more
likely to experience loss in BMD than patients
adherent with treatment.30
Overall, 5.9% of patients reported a fracture in the
present study. There is large variation in fracture rates
reported for similar studies.9,16,21,23 The CANDOO
study found only 2% of patients experienced an
incident fracture within 2 years of starting1692osteoporosis treatment, which was independently
associated with a history of nonvertebral fracture.21
In contrast, most studies have reported a higher
fracture rate for patients undergoing treatment,9,16,23
which may be attributed to both patient character-
istics and study design. For example, 13.5% of
patients in the present study had a history of fractures
at baseline compared with 67% to 100% in studies
reporting higher fracture rates.9,16,23 Furthermore, the
present study only considered patient-reported clinical
fractures, whereas previous studies have also consid-
ered morphometric fractures.9 It is likely, therefore,
that fracture incidence may be underestimated in the
present study.
Previous studies have examined treatment success
or failure based on whether patients experienced bone
loss or fractures after commencement of treat-
ment.9,16,18,20,23 A determination of treatment success
or failure in the present study was not assessedVolume 38 Number 7
D. Mellstro¨m et al.because the study did not measure adherence through-
out the follow-up period and as such may include
patients who were nonadherent to treatment. Evi-
dence suggests that adherence to osteoporosis treat-
ment is low after a fracture, with more than half
(58%) of patients with a fracture, an indication for
treatment (as indicated by BMD), and subsequently
prescribed osteoporosis treatment stopping use of
their medication within 6 months.31 By including
potentially nonadherent patients, this study provides
evidence of real-world treatment effectiveness, where
patients may not always be adherent to treatment,
which may more accurately inform high fracture risk
in patients taking osteoporosis medications.
Osteoporosis treatment patterns varied within the
osteoporosis and BMD decrease cohorts compared
with all eligible patients in the study. Osteoporosis
therapy was self-reported by patients, and information
pertaining to osteoporosis treatment prescribing was
unable to be ascertained from the registry data.
Factors such as disease severity, fracture risk factors,
and current treatment recommendations may have
had an inﬂuence on treatment effectiveness and
BMD outcomes. No comparisons in treatment rates
are made between the 2 groups. Almost three-quarters
(72.4%) of patients in the osteoporosis cohort re-
ported using bisphosphonates. Most (53.3%) in the
BMD decrease cohort used raloxifene. One explan-
ation for the resultingZ3% decrease in T score in this
group could be that raloxifene is less effective in
preventing BMD decrease than bisphosphonates
among older Swedish adults. Irrespective, evidence
suggests that patients who experience a BMD decrease
while undergoing treatment still have greater protec-
tion against fracture than untreated patients with the
same level of BMD loss.10 A further possibility may be
patients in the BMD decrease cohort switching to
raloxifene during follow-up if they were nonrespon-
sive to bisphosphonate therapy. This theory can only
be speculated because osteoporosis treatment success
or failure was not established through adherence data,
and the reasons, either clinical or preferential, for the
prescribing of particular osteoporosis medications by
the treating physician has not been investigated.
As with all studies, certain limitations are inevi-
table, and the results should be considered in this
context. Because of the nature of the study, further
comparative statistical analysis was not possible,
and no analyses were conducted to control forJuly 2016confounding factors, such as treatment adherence,
age, and type of medication. Most patients were
female (92.3%), and thus the results may not be
representative of the broader population at risk of
hip fracture. osteoporosis treatment use and fracture
incidence relied on self-reported patient data during a
2-year period in an older population and as such may
be subject to recall bias and potential inaccuracies.
Furthermore, because the study was descriptive in
nature, no formal comparisons were made in baseline
assessment, outcomes, or characteristics between the
cohorts. Any differences in treatment patterns during
the period of the study may have been inﬂuenced by
changes in treatment guidelines to reﬂect current
practice at the time of each assessment. A common
challenge in longitudinal studies is the attrition rate.
Almost half of osteoporotic patients identiﬁed through
the registry did not return for a follow-up visit, and as
a result, fracture and BMD data for these patients
could not be captured. No comparisons were con-
ducted between patients lost to follow-up and in-
cluded study participants. Therefore, signiﬁcant
differences in patient characteristics, such as age,
number of fractures, falls rate, smoking history, or
treatment adherence, may have biased the study
results. In addition, patients who stopped osteoporosis
treatment before the ﬁrst follow-up visit were not
included in the current analysis. Osteoporosis medi-
cation adherence data were not recorded, and poor
adherence by some patients may have negatively
affected the change in T scores and implying inad-
equate treatment response. No patients reported using
zoledronic acid, denosumab, or teriparatide; however,
these are not ﬁrst-line therapies in Sweden and would
be uncommon in a treatment-naive population. Data
collected from the registry dated back to 1991, and
Swedish osteoporosis guidelines have since been
updated.CONCLUSION
Many patients in Sweden may remain osteoporotic
and at high risk of fracture even after 2 years of
osteoporosis treatment. The study highlights the need
to further investigate the effect of osteoporosis treat-
ment on BMD in patients with osteoporosis in
Sweden. Such investigations will aid in developing
effective, evidence-based treatment strategies to
reduce fracture risk and improve patient outcomes in1693
Clinical Therapeuticsthe real-world setting. Further improvements in pa-
tient and clinical outcomes can be achieved through
supportive measures, such as promoting patient ad-
herence to therapy, reinforcing lifestyle habits, and
close monitoring of therapeutic response to pharma-
cotherapy, to ensure maximum beneﬁt to the patient is
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Appendix.-Swedish Osteoporosis Registry database, quest
1. Fractures. 
1a. Have you had a fracture after the age of 40?  
Yes No   
1b. If yes, what kind of fracture at which age?   
Wrist      Age  
Ankle      Age 
Upper arm      Age 
Vertebral fracture    Age 
Vertebral compr ession    Age  
Hip/femoral neck     Age 
Other fracture   
2. Back pain.  
2a. Are you currently suffering from daily pain? 
Yes   No   
2b. If yes, to which extent does the back pain affects y
No impact 
Hamper activities  
Makes some tasks impossible to do 
2c. Do you take pain killers for you back pain every da
Yes No   
3. Length 
3a. Length (cm) at the age of 25: 
3b. Weight (kg) at the age of 20-25 years: 
4. Heredity.  
4a. Did your mother have a hip fracture?  Yes 
4b. Did your mother suffer from kyphosis? Yes 
 4c. Did your mother suffer from other fracture?  Yes 
4a. Did your father have a fracture?   Yes 
5. Questions to women regarding menstruation etc 
5a. If you have entered menopause, at what age?   
5b. At which age did you get your first period?  
5c. Have you by surgery removed your ovaries?  
5d. Have you by surgery removed your uterus?  
5e. Number of children 
5f. Have you breast fed any of your children more than
6. Smoking.  
Never smoked   
Previous smoker  Start
Smoker    Start
Number of cigarettes per day 1-10   11-20
7. EQ-5D.  
7a. Mobility 
7b. Hygiene 
7c. Activities 
7d. Pain/difficulties 
7e. Anxiety 
1695.e1ionnaire 
our daily activity? 
y? 
No   Don’t know   
No   Don’t know   
No   Don’t know   
No   Don’t know   
 Age: 
 Age: 
 Yes No   
 Yes No   
 9 months?  Yes No   
ed at age: , stopped at age: 
ed at age: 
>20
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How many times have you been falling during the last year
9. Regarding drug treatment for osteoporosis.
9a. Do you currently take any drug for treatment of osteopo
Fossamax 70 mg weekly Used the drug for ____ 
Fossamax 10 mg  Used the drug for ____ 
Optinate Septimum weekly Used the drug for ____ 
Optinate 5 mg   Used the drug for ____ 
Didronate   Used the drug for ____ 
Evista    Used the drug for ____ 
Calcium + D-vitamin   Used the drug for ____ 
Specification of Ca/D vit drug:_______________________
Estrogen   Used the drug for ____ 
Specification of estrogen drug:_______________________
Forsteo    Used the drug for ____ 
9b. Have you previously taken any drug for treatment of os
Fossamax 70 mg weekly Used the drug for ____ 
Fossamax 10 mg  Used the drug for ____ 
Optinate Septimum weekly Used the drug for ____ 
Optinate 5 mg   Used the drug for ____ 
Didronate   Used the drug for ____ 
Evista    Used the drug for ____ 
Calcium + D-vitamin   Used the drug for ____ 
Specification of Ca/D vit drug:_______________________
Estrogen   Used the drug for ____ 
Specification of estrogen drug:_______________________
Forsteo    Used the drug for ____ 
9c. Have stopped taking any of the mentioned drugs – why
Other reason   
10. Cortison.
10a. Do you take cortison?    
Yes   No   
Taken cortison tablets for ______ years and ______ month
10b. Have you previously taken cortison tablets but stoppe
Yes   No   
Taken cortison tablets for ______ years and ______ month
11. Other diseases.
Have you been diagnosed with any of the following disease
High blood preasure  
Diabetes   
Hyperthyrodism   
Crohn’s disease/ulcerous colitis 
Celiac disease   
Rheumatic disease  
Asthma/chronic respiratory disease   
Parkinson   
Stroke with paralysis  
Other chronic disease  
Polymyalgia (Temporalis arthritis)   
July 2016? 0 1-2 3-4 >5
rosis?  Yes No   
years and ____ months 
years and ____ months 
years and ____ months 
years and ____ months 
years and ____ months 
years and ____ months 
years and ____ months 
____________________ 
years and ____ months 
___________________ 
years and ____ months 
teoporosis?  Yes No   
years and ____ months 
years and ____ months 
years and ____ months 
years and ____ months 
years and ____ months 
years and ____ months 
years and ____ months 
____________________ 
years and ____ months 
___________________ 
years and ____ months 
? 
s 
d?  
s and stopped year:______ 
s by your physician; 
1695.e2
Clinical TherapeuticsNOT TO BE FILLED OUT BY THE PATIENT, NOTES MAD
Date   DXA machine   Len
1. 
2. 
3. 
4. 
5. 
Lumbar spine      Tot
BMD   T-score   BM
1. 
2. 
3. 
4. 
5. 
Total body 
 BMD   T-score 
1. 
2. 
3. 
4. 
5. 
Diagnosis matrix 
Normal BMD     - 1 
Ostepenia     M85.9 2 
Osteoporosis     M81.0 3 
Established osteoporosis   M80.0 4 
Idiopatic osteoporosis (men)   M81.5 5 
Established idiopatic osteoporosis (men) M80.5 6 
Liver transplantation    Yes   
Primary hyperparathyrodism Yes   
Celiac disease     Yes   
Newly discovered secondary osteoporosis Yes   
Other known secondary osteoporosis  Yes   
RA      Yes   
KOL      Yes   
Polymyalgia     Yes   
Referral sent by 
Gynecologist 
Rheumatologist 
Orthopedian 
Primary care 
Other  
1695.e3E BY THE CLINIC 
gth (cm) Weight (kg) 
al hip 
D  T-score 
No   
No   
No   
No   
No   
No   
No   
No   
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